Meeting NewsVideo

VIDEO: ReNetX Bio’s neuroprotection technology promising for glaucoma treatment

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, James C. Tsai, MD, MBA, president of New York Eye and Ear Infirmary of Mount Sinai and chair of the department of ophthalmology at Icahn School of Medicine at Mount Sinai, discusses neuroprotection technology from ReNetX Bio for glaucoma. The new biologic protein enhances regeneration of dead or damaged retinal ganglion cells, he said.

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, James C. Tsai, MD, MBA, president of New York Eye and Ear Infirmary of Mount Sinai and chair of the department of ophthalmology at Icahn School of Medicine at Mount Sinai, discusses neuroprotection technology from ReNetX Bio for glaucoma. The new biologic protein enhances regeneration of dead or damaged retinal ganglion cells, he said.

    See more from Glaucoma 360